Has Madan Arora received payments from drug or device companies?

Yes. Drug and device makers reported $84,245 in general payments to Madan Arora across 467 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Madan Arora did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Madan Arora come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Madan Arora

Hematology & Oncology · Flint, MINPI 1760463731

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $51,105 of the $84,245 with a category attached, or 60.7%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.2%. Reporting peaked in 2019 at $25,186 and has fallen 94.6% since, to $1,350 in 2025. Among hematology & oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,245in general payments, 2019–2025

Across 467 payments — averaging $180.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Seagen Inc.$19K
AstraZeneca$12K
Gilead$8K
Bristol Myers Squibb$8K
Pharmacosmos Therapeutics Inc.$5K
Acceleron Pharma, Inc.$3K
plus $29K from 54 others

What the payments were for

Consulting fees$51,10561%
Speaking & faculty fees$16,26019%
Travel & lodging$7,3199%
Food & beverage$8,79010%
Education$7711%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Seagen Inc.	27	$18,727
AstraZeneca(2 entities)	43	$11,855
Gilead(2 entities)	21	$8,473
Bristol Myers Squibb	26	$7,889
Pharmacosmos Therapeutics Inc.	6	$5,202
Acceleron Pharma, Inc.	1	$3,250
E.r. Squibb & Sons, L.L.C.	19	$2,403
Heron Therapeutics, Inc.	3	$2,386
Athenex Pharmaceutical Division, LLC	5	$2,217
GSK	7	$2,147
Dova Pharmaceuticals	3	$1,863
Novartis	7	$1,455
Regeneron Healthcare Solutions, Inc.	2	$1,338
Epizyme, Inc.	4	$1,314
Beigene USA, Inc.	5	$1,209
Secura Bio, Inc.	1	$1,200
Bayer	7	$1,171
Johnson & Johnson(2 entities)	34	$1,085
AMAG Pharmaceuticals, Inc.	6	$1,020
Sanofi	22	$835
Karyopharm Therapeutics Inc.	4	$806
Genentech USA, Inc.	30	$602
EMD Serono, Inc.	6	$588
Astellas Pharma US Inc	4	$550
Sanofi-aventis U.S. LLC	4	$469
Beigene, Ltd.	1	$450
Amgen	20	$402
Merck	18	$382
Takeda Pharmaceuticals U.S.A., Inc.	13	$342
Eisai Inc.	8	$284
Pfizer	22	$240
Incyte Corporation	10	$235
Novocure GmbH	1	$200
Exelixis Inc.	5	$143
Lilly USA, LLC	7	$136
Tesaro, Inc.	5	$135
Pharmacyclics LLC, An Abbvie Company	5	$125
Jazz Pharmaceuticals Inc.	6	$118
Ipsen Biopharmaceuticals, Inc	5	$112
Comsort, Inc	1	$100
Coherus Oncology, Inc.	2	$82
AbbVie	4	$73
Puma Biotechnology, Inc.	5	$73
Daiichi Sankyo Inc.	2	$59
Clovis Oncology, Inc.	3	$53
Tersera Therapeutics LLC	3	$41
Agios Pharmaceuticals, Inc.	2	$40
Taiho Oncology, Inc.	2	$40
Mylan Institutional Inc.	2	$37
CSL Behring	2	$33
Morphosys, US Inc.	2	$32
Array Biopharma Inc	2	$29
Innate Pharma, Inc	1	$29
Rigel Pharmaceuticals, Inc.	1	$19
Boehringer Ingelheim	1	$19
Blue Earth Diagnostics	1	$17
Blueprint Medicines Corporation	1	$16
Foundation Medicine, Inc.	1	$15
Deciphera Pharmaceuticals Inc.	1	$15
Servier Pharmaceuticals LLC	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

TIVDAK$8,688
LYNPARZA$7,865
Yescarta$6,442
Monoferric$4,989
BB-2121$4,639
ADCETRIS$4,189
FARYDAK$3,600
Reblozyl$3,250
CINVANTI$2,336
SUSTOL$2,336
DOPTELET$1,750
Tecartus$1,700
LIBTAYO$1,660
Luspatercept$1,600
BRUKINSA$1,575
TAZVERIK$1,250
Stivarga$1,000
FERAHEME$949
OPDIVO$830
Oral Paclitaxel$800

How this compares

$84,245 in reported general payments places this provider in the 95th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan →

Other hematology & oncology in Flint

Rizwan DanishFlint$43K
T SinghFlint$9K
Alyssa KipkeFlint$8K
Venkatasiva PeramFlint$8K
Faisal MusaDearborn$976K
Mohammed Al HallakDetroit$644K
Daniel LebovicGrosse Pointe Woods$352K
Sreenivasa ChandanaGrand Rapids$305K
Mohammad ChistiTroy$180K
Gordon SrkalovicLansing$167K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →